Solve.Care Teams With Boehringer Ingelheim On Blockchain Care Network For Diabetes Patients

Blockchain healthcare startup Solve.Care has teamed with pharmaceutical company Boehringer Ingelheim to develop a blockchain and cryptocurrency-powered network.

Based in Estonia, Solve.Care offers a healthcare administration and care coordination platform that uses blockchain technology as the underlying distributed ledger for coordinating care, benefits and payments between patient, doctor, pharmacy, laboratory, employer, insurer, and all other parties. The firm’s Care.Wallet app is available for download in more than 80 countries on App Store and Google Play.

Solve.Care is working with Boehringer Ingelheim, one of the world’s 20 largest pharma companies, to launch the Diabetes Care Administration Network, which is designed to improve the well-being of patients with diabetes, and who may also be at an increased risk for cardiovascular disease. The network will implement Solve.Care’s Care.Wallet app in order to support patients with the disease.

“The Diabetes Care Administration Network will help bridge a knowledge gap by providing a platform which offers vital information on diabetes and cardiovascular diseases in an easily accessible manner,” said Pradeep Goel, CEO of Solve.Care. “This is invaluable in the healthcare ecosystem as it allows patients to gain a better understanding of their disease while also coordinating their care needs.”

The Diabetes Care Administration Network will be piloted by the Arizona Care Network (ACN), an accountable care organization in the US and a current client of Solve.Care. ACN will provide concierge care management and support care coordinators, with the goal of achieving better healthcare outcomes for participating patients. Based on the results of this pilot, expansion opportunities in the US and globally will be evaluated.

“We are proud to join Solve.Care and the Arizona Care Network to provide patients and providers with additional solutions to help address diabetes and cardiovascular disease,” said Graham Goodrich, vice president, Cardiometabolic Marketing, Boehringer Ingelheim Pharmaceuticals, Inc. “Recent changes to diabetes treatment recommendations have prioritized managing cardiovascular risk, and this program will help ensure both patients and providers are proactively addressing life-threatening cardiovascular complications associated with this chronic condition.”

Source: Read Full Article